Roche: new positive data for glofitamab
(CercleFinance.com) - Roche announces that new positive pivotal data on its glofitamab will be presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting on 3-7 June and the European Hematology Association (EHA) on 9-12 June.
The data, presented for the first time, shows that glofitamab induces high and sustained complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma, according to the Swiss healthcare giant.
The data has been submitted for approval to the European Medicines Agency (EMA), with submissions to other health authorities, including the US FDA, are expected this year.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The data, presented for the first time, shows that glofitamab induces high and sustained complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma, according to the Swiss healthcare giant.
The data has been submitted for approval to the European Medicines Agency (EMA), with submissions to other health authorities, including the US FDA, are expected this year.
Copyright (c) 2022 CercleFinance.com. All rights reserved.